Is TSW Becoming More Accepted in Dermatology? With Brad P. Glick, DO, MPH

Topical steroid withdrawal (TSW) syndrome is considered by some to be a controversial topic in the 

 world today, but it is becoming more widely discussed among clinicians and patients.

Brad Glick, DO, MPH, a board-certified dermatologist and dermatologic surgeon known for his role at the Glick Skin Institute, spoke with the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, Colorado, about this topic and others covered in his session at the conference. He was first asked whether TSW is becoming more accepted as a real condition in the dermatology space.

“[Just] ask the country of Canada…and Great Britain, where there are now specific warnings and package inserts for topical corticosteroids, about TSW,” Glick expressed.

He addressed the growing recognition of TSW, describing the condition as increasingly supported by emerging research and international regulatory acknowledgment around the world. Glick added, despite some remaining skepticism within the dermatology community, that mounting data and patient presentations are contributing to TSW’s broader acceptance as a real condition.

From a clinical standpoint, he described several characteristic features to aid clinicians in their identification of TSW. Such characteristics include diffuse erythema, especially involving the face, as well as more distinctive findings such as the “sleeve sign.” This sign is marked by the sharp demarcation of erythema located on patients’ wrists or ankles, as well as erythema of the lower extremities.

Glick further referenced recent mechanistic insights suggesting a potential role for metabolic pathways, including NADH-related processes, in driving rebound inflammation following chronic or moderate topical corticosteroid use, potentially helping to clarify the pathophysiology underlying TSW.

Additionally, he pointed to the role of patient awareness and social media in amplifying recognition of TSW. Specifically, Glick described a marked increase in inquiries among patients following educational presentations on the subject. Despite acknowledgement of online discourse sometimes overstating various concerns, he emphasized that clinicians are encountering individuals with symptoms aligned with TSW in clinical practice.

 with a broader perspective on therapeutic innovations in dermatology in 2026. Glick pointed to the expansion of non-steroidal topical agents’ availabilities as a notable advancement, adding that such shifts may help patients’ disease control and may diminish their reliance on intermittent corticosteroid use. Later, Glick noted the sustained impact of biologic drugs in the current armamentarium, particularly in psoriasis and atopic dermatitis.

Looking ahead, Glick expressed optimism regarding the development of novel oral medications, and this was described by Glick as especially true for psoriasis. Such developments may complement existing biologic and topical options for patients with dermatologic diseases. Nevertheless, the critical barrier of access was cited by Glick as remaining, with prior authorization requirements being described as a persistent obstacle.

The quotes used in this interview summary were edited for clarity.

Glick has served as an adviser, consultant, speaker, or investigator for Amgen, AbbVie, AstraZeneca, Almirall, Arcutis, Bausch Health/Valeant, Ortho Dermatologics, Boehringer Ingelheim, Bristol-Myers Squibb, Brickell Biotech, Cara, ChemoCentryx, Dermavant, Dermira, Eli Lilly, EPI/Novan, Incyte, Janssen Pharmaceuticals, LEO Pharma, Galderma, Nimbus Lakshmi, Inc, Novartis, Sun Pharma, Pfizer, Sanofi, Regeneron, UCB and the CorEvitas AD, CorEvitas PSO, and PROSE Registries and is a shareholder of Top MD

Lio P. Addressing Doubts About Topical Steroid Withdrawal (TSW), with Peter Lio, MD. HCPLive. June 10, 2025. Accessed December 12, 2025. 

https://www.hcplive.com/view/addressing-doubts-about-topical-steroid-withdrawal-tsw-peter-lio-md

Glick B, et al. S065 What's New in Dermatology. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Videos

In this interview from AAD 2026, Glick speaks about key insights on topical steroid withdrawal (TSW) and on the future of dermatology.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has accepted a supplemental New Drug Application (sNDA) for delgocitinib (Anzupgo) cream for the treatment of moderate-to-severe 

"Pediatric patients living with chronic hand eczema currently have no approved treatment options specifically indicated for CHE, representing a significant unmet medical need," said Bob Spurr, executive vice president and president of Region North America at LEO Pharma.

Announced on April 15, 2026 by LEO Pharma, the filing acceptance marks the first regulatory review pathway in the United States specifically targeting the pediatric age group for CHE. The announcement comes less than 1 year after delgocitinib cream became the first therapy to receive 

FDA approval for CHE in adults in July 2025

 Topical, non-steroidal pan-JAK inhibitor

 FDA sNDA accepted for review; April 2026

The sNDA is supported by data from DELTA TEEN (NCT05355818), a 16-week, phase 3, randomized, double-blind, vehicle-controlled, parallel-group, multicenter trial evaluating twice-daily applications of delgocitinib cream 20 mg/g versus cream vehicle in patients aged 12 to 17 years with moderate to severe CHE for whom topical corticosteroids were inadequate or inappropriate.¹

The primary endpoint was Investigator's Global Assessment for CHE treatment success (IGA-CHE TS) at week 16, defined as an IGA-CHE score of 0 or 1 with at least a 2-step improvement from baseline.¹ The trial met its primary endpoint and key secondary endpoints, with detailed 

efficacy and safety results presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress 2025

Delgocitinib is a topical, non-steroidal pan-JAK inhibitor that suppresses JAK-STAT signaling, a pathway central to the inflammatory cascade implicated in CHE pathogenesis. LEO Pharma acquired exclusive rights to develop and commercialize delgocitinib for topical dermatological use outside Japan in 2014 while Shionogi & Co., Ltd. retains Japanese rights.

In adults, delgocitinib cream received FDA approval in July 2025 for moderate to severe CHE in patients who have had an inadequate response to, or for whom TCS are not advisable.² The product is also approved in the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea, and the United Arab Emirates for the same adult indication.

The class-level safety profile of JAK inhibitors warrants attention in any new population. The US prescribing information for delgocitinib carries warnings regarding serious infections, non-melanoma skin cancer risk, and theoretical risks extrapolated from oral JAK inhibitor data, including cardiovascular mortality in higher-risk adults, but it is not established whether topical application confers equivalent systemic risk.² Common adverse effects reported with delgocitinib in adults include application site reactions, bacterial skin infections, and decreased white blood cell counts.²

FDA review timelines and a Prescription Drug User Fee Act (PDUFA) target action date were not disclosed in the announcement. The EMA review for the same indication is ongoing, but has not reached a regulatory decision.

LEO Pharma. LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-17. Leo-pharma.com. Published April 15, 2026. Accessed April 15, 2026. 

https://www.leo-pharma.com/media-center/news/2026-acceptance-of-anzupgo-snda

LEO Pharma. LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S. Business Wire. Published July 23, 2025. Accessed April 15, 2026. 

https://www.businesswire.com/news/home/20250723974453/en/LEO-Pharma-Announces-FDA-Approval-of-ANZUPGO-delgocitinib-Cream-in-the-U.S.

Campbell P. DELTA TEEN: Delgocitinib Proves Benefit in Teens with Chronic Hand Eczema. Hcplive.com. Published September 18, 2025. Accessed April 15, 2026. 

https://www.hcplive.com/view/delta-teen-delgocitinib-proves-benefit-in-teens-with-chronic-hand-eczema

Articles

LEO Pharma’s FDA-accepted sNDA seeks to extend topical delgocitinib (ANZUPGO) to adolescents (12–17) with moderate-to-severe chronic hand eczema inadequately controlled with, or inappropriate for, topical corticosteroids. The application is supported by the 16-week phase 3 DELTA TEEN RCT, which reportedly achieved IGA-CHE treatment success and key secondary endpoints, though full peer-reviewed data remain pending. If approved, this would address an adolescent-specific therapeutic gap. Interpretation should incorporate JAK-class warnings and limited long-term pediatric safety data.

The FDA has accepted LEO Pharma's sNDA for delgocitinib cream for moderate-to-severe chronic hand eczema in adolescents. 

FDA News

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

FDA Accepts Delgocitinib sNDA for Chronic Hand Eczema in Adolescents Aged 12–17

Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

Invasive Treatment Options in Hypertrophic Cardiomyopathy 

In the final episode, Invasive Treatment Options in Hypertrophic Cardiomyopathy, the panelists explored the following critical question:

What is the role of invasive procedures for hypertrophic cardiomyopathy?

Led by the moderator, the experts examine invasive procedures, which play a critical role in the management of hypertrophic cardiomyopathy (HCM) for patients who remain symptomatic despite optimal medical therapy. Septal myectomy and alcohol septal ablation are the primary interventions used to reduce left ventricular outflow tract obstruction and improve symptoms such as dyspnea, chest pain, and syncope. These procedures are typically considered for patients with severe obstruction or functional limitations, and careful patient selection is essential to optimize outcomes. When performed by experienced centers, invasive interventions can significantly improve quality of life, functional capacity, and long-term prognosis in patients with obstructive HCM.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this HCP Live Peer Exchange series on hypertrophic cardiomyopathy. Please subscribe to our newsletter for information on upcoming video series.

Learn when cardiac myosin inhibitors suffice and when myectomy or alcohol ablation fits, with shared decisions at expert HCM centers.

Video Series

Insights from the MAPLE Trial: Clinical Implications for oHCM Management 

This episode, titled Insights from the MAPLE Trial: Clinical Implications for oHCM Management, features panelists discussing the following question:

Can you please discuss the MAPLE trial and its clinical implications?

Led by Dr. Maron, Drs. Harper, Le, and Rader examined the MAPLE trial, which provides important comparative data on the efficacy and safety of aficamten versus standard therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. Findings from the study highlight improvements in hemodynamic parameters, symptom burden, and functional capacity, supporting the role of cardiac myosin inhibition as a targeted treatment approach. The trial also offers insight into how newer therapies may fit into existing treatment algorithms alongside traditional agents. These results have meaningful clinical implications, particularly in guiding personalized treatment decisions and optimizing patient outcomes in real-world practice.

In the next episode, Invasive Treatment Options in Hypertrophic Cardiomyopathy, panelists will continue their discussion on the role of invasive procedures, such as septal myectomy and alcohol septal ablation, in the management of hypertrophic cardiomyopathy. It highlights patient selection, expected outcomes, and how these interventions fit within the broader treatment landscape.

MAPLE HCM reveals aficamten beats beta blockers in obstructive HCM, reshaping first-line therapy debates amid insurance hurdles.

Differentiating Cardiac Myosin Inhibitors: Clinical Considerations and Drug Interactions

In Differentiating Cardiac Myosin Inhibitors: Clinical Considerations and Drug Interactions, our panel/experts delve(s) into the following critical questions:

How are you differentiating between the 2 FDA-approved cardiac myosin inhibitors, mavacamten and aficamten?

Do the different pharmacokinetics between the 2 impact your treatment decisions?

Led by Dr. Martin Maron, the Drs. Harper, Rader, and Le discuss differentiation between mavacamten and aficamten, which often centers on their pharmacokinetic profiles, including half-life, time to steady state, and flexibility in dose adjustments. These differences can influence how quickly clinicians can titrate therapy and respond to changes in patient status or adverse effects. Aficamten’s shorter half-life may allow for more rapid dose optimization and potentially easier management in situations requiring interruption, while mavacamten’s longer half-life may require more cautious adjustments. As a result, pharmacokinetics can play an important role in treatment decisions, particularly when considering patient-specific factors such as comorbidities, concomitant medications, and the need for close monitoring.

Explore how aficamten’s shorter half-life enables faster titration, flexible echo monitoring, and fewer drug interactions—making HCM treatment more patient-friendly and accessible.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and see why patients breathe easier.

Advancing Cardiac Myosin Inhibitor Therapy: Evidence, Monitoring, and Clinical Integration

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Ambitious psoriasis remission targets spark clinician debate, urging treatment tweaks to achieve sustained clearance, improve quality of life, and reduce comorbidity risks.

Patient Communication in Psoriasis Remission

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and learn why patients breathe easier.

Monitoring Treatment Response and Advancing Therapy in Obstructive HCM 

Experts share treat-to-target psoriasis goals, when to switch biologics, and how near-clear skin may reduce arthritis risk.

Remission as a Goal in Psoriasis

Learn key hypertrophic cardiomyopathy symptoms and how echoes with Valsalva or exercise reveal hidden LVOT obstruction for accurate diagnosis.

The Importance of Early Diagnosis and Treatment in Obstructive HCM

Learn when IV iron beats pills for anemia after bariatric surgery, IBD, celiac, GAVE and angiectasias—plus key endoscopy steps.

Special Populations — IDA After Bariatric Surgery, in IBD, Portal Hypertensive Gastropathy, GAVE, Celiac Disease, and Small Bowel Angioectasia 

King discusses real-world patient use of AI tools for mental health advice and implications for clinical conversations.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Clinicians Encounter Patient Use of AI for Mental Health, With Darlene King, MD

Alexander Blood, MD, is the associate director of the Massachusetts General Brigham Accelerator of Clinical Transformation, an instructor in medicine at Harvard Medical School, and co-founder and CEO of AIwithCare.

Blood discusses his recent study of the RECTIFIER AI model, highlighting its superior sensitivity and accuracy compared to physicians.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Strategic Alliance Partnership

AI Model Outperforms Clinicians in HCM Registry Data Extraction, With Alexander Blood, MD

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

Pranav discusses the necessity for addressing the structural barriers that remain for living donor kidney transplantations in black patients. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Rebuilding Trust, Increasing Living Donor Transplant In Black Kidney Candidates, With Pranav Garimella, MBBS, MPH

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This phase 2b study on brensocatib did not meet its primary or secondary efficacy endpoints, causing Insmed to discontinue their HS program.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Latest News

Is TSW Becoming More Accepted in Dermatology? With Brad P. Glick, DO, MPH

FDA Accepts Delgocitinib sNDA for Chronic Hand Eczema in Adolescents Aged 12–17

Invasive Treatment Options in Hypertrophic Cardiomyopathy

Insights from the MAPLE Trial: Clinical Implications for oHCM Management

Differentiating Cardiac Myosin Inhibitors: Clinical Considerations and Drug Interactions